<DOC>
	<DOCNO>NCT00897208</DOCNO>
	<brief_summary>RATIONALE : Studying sample nipple fluid , urine , blood laboratory patient cancer patient risk develop cancer may help doctor identify learn biomarkers related cancer . It may also help doctor learn breast cancer identify patient risk develop breast cancer . PURPOSE : This laboratory study look biomarkers nipple fluid , urine , blood sample woman newly diagnose ductal carcinoma situ stage I stage II breast cancer woman risk develop breast cancer .</brief_summary>
	<brief_title>Studying Biomarkers Nipple Fluid , Urine , Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ Stage I Stage II Breast Cancer Women Risk Developing Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine level catechol estrogen ( CE ) , CE metabolites , CE-DNA adduct , CE conjugate nipple aspirate fluid sample obtain woman newly diagnose ductal carcinoma situ stage I II breast cancer woman high risk develop breast cancer . OUTLINE : Patients newly diagnose breast cancer high risk develop breast cancer undergo nipple aspiration . The nipple aspirate fluid obtain unaffected breast analyze 31 estrogen metabolite , conjugate , depurinating DNA adduct high-performance liquid chromatography ( LC ) electrochemical mass spectrometric detector . All patient undergo urine serum sample collection . The urine sample analyze ultraperformance LC monitor tandem mass spectrometry estrogen metabolite , conjugate , depurinating DNA adduct . Patients ' chart review obtain information age , race , general health , endocrine disorder , history cancer , estrogen progesterone receptor status , HER2/neu status ( patient newly diagnose breast cancer ) , menopausal status , reproductive history , history breast disease , medication use , smoke history , history alcohol consumption .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Newly diagnose ( within 30 calendar day diagnosis ) stage I II breast cancer Nodenegative nodepositive disease Newly diagnose ductal carcinoma situ ( stage 0 ) breast At high risk develop breast cancer , indicate least 1 follow criterion : Gail model 5year risk score ≥ 1.66 % Gail model lifetimerisk estimate ≥ 20 % Known deleterious BRCA 1 2 gene mutation carrier History lobular carcinoma situ atypical ductal lobular hyperplasia At low average risk develop breast cancer ( control group ) Gail model 5year risk score &lt; 1.66 % lifetime risk &lt; 20 % No advance breast cancer Hormone receptor status specify PATIENT CHARACTERISTICS : Pre postmenopausal PRIOR CONCURRENT THERAPY : No prior chemotherapy breast cancer cancer More 3 month since prior concurrent estrogen hormone More 3 month since prior oral contraceptive No concurrent selective estrogen receptor modulators ( tamoxifen citrate raloxifene ) No concurrent aromatase inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>